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 Introduction 
 The occurrence of body cavity effusions is always a 
symptom of a considerable pathologic process. The etiol-
ogy of effusions comprises a wide spectrum of diseases 
ranging from nonneoplastic ones, such as posttraumatic, 
inflammatory (infection or connective tissue diseases), 
circulatory (congestive heart failure and central lymphat-
ic obstruction), and kidney or liver dysfunction disorders, 
to manifestations of any kind of malignancy, either 
spreading from other organs (lungs, breasts, ovaries, and 
pancreas, etc.) or being primary [mesotheliomas and pri-
mary effusion lymphomas (PEL)]. Malignant pleural ef-
fusions are common in patients with hematologic malig-
nancies and they are reported to occur – depending on 
the specific entity – in up to 48% of such patients  [1–3] , 
while involvement of the peritoneal and pericardial cavi-
ties seems to be less common. Up to 10% of malignant 
pleural effusions with a positive cytologic examination 
are due to non-Hodgkin lymphoma (NHL). In the vast 
majority of cases, serous effusions develop during the 
course of the disease, but rarely they may be the first pre-
sentation of a hematologic malignancy. The pathogenesis 
of effusions in lymphomas and hematologic neoplasias is 
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 Abstract 
 Cytopathologists are regularly confronted with lympho-
cyte-rich effusions, and the definite decision of whether 
the lymphocytosis is of a purely reactive nature or a presen-
tation of an indolent lymphoma may be an extremely dif-
ficult one based on microscopy alone. Flow cytometry (FC) 
offers many advantages in terms of its application in body 
cavity fluids, and it has proven to be very useful both in the 
setting of a known disease and for new lymphoma diagno-
ses. In this paper, the studies published in recent years 
dealing with the applications of FC in body cavity effusions 
in the context of hematologic neoplasia are reviewed, 
stressing the integrative diagnostic approach. The incor-
poration of microscopical, immunophenotypical, and mo-
lecular findings from examinations of the cellular content 
of effusions and the interpretation of results in relation to 
the current WHO classification of hematolymphoid ma-
lignancies give cytopathologists new perspectives on ad-
vanced and clinically highly relevant diagnostics. 
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considered to be multifactorial. The most common cause 
is infection due to an impaired immune system during 
the course of the disease or its treatment. Impaired lym-
phatic drainage as a result of mediastinal lymph node en-
largement, thoracic duct obstruction, venous obstruc-
tion, increases in vascular permeability, and radiation-
associated changes, as well as infiltration of the serosal 
membranes by the tumor, probably all contribute in the 
pathogenesis of effusions in this setting. The presence of 
cells of a hematologic malignancy in effusions is usually 
a sign of advanced and generalized disease. In most cases, 
it causes substantial morbidity and requires treatment. In 
the study of Gilbert et al.  [1] , among 91 patients with he-
matologic disease requiring placement of an indwelling 
pleural catheter, 62% had a diagnosis of a lymphoma, fol-
lowed by leukemia (21%), and multiple myeloma (13%), 
with 4 patients having either amyloidosis or myelofibro-
sis.
 While the presence of carcinoma, mesothelioma, or 
sarcoma cells in pleural effusions is microscopically obvi-
ous in most cases, the diagnosis of lymphoma cells in flu-
ids – especially of the indolent lymphoma subtypes – may 
be challenging for several reasons. The cells of low-grade 
NHL usually have a deceptively bland cytologic appear-
ance, while cells in reactive conditions may show a strik-
ing atypia. The possibility of characterizing individual 
cells according to their surface antigenicity by flow cy-
tometry (FC) offers the chance to precisely subclassify the 
cells and sort them into separate populations. Body cav-
ity fluids, as suspensions of well-preserved, viable cells, 
are well suitable for this kind of study.
 Immunophenotyping by FC is a well-established diag-
nostic method in the hands of hematologists for the de-
tection and subtyping of hematolymphoid malignancies 
in blood, lymph nodes, bone marrow, and other organs. 
The incorporation of this method into routine cytopatho-
logic diagnostics appears to be less well established and 
varies among institutions; however, it has become more 
and more generally accepted in recent years, primarily in 
the setting of fine-needle aspirations (FNA) but also in-
creasingly for the study of the composition of the cellular 
content of body fluids. The application of FC by cytopa-
thologists is feasible and rewarding in relation to the di-
agnostic yield, especially when combined with the appli-
cation of other ancillary techniques, such as immunohis-
tochemical and molecular methods. As the diagnostic 
criteria of hematologic diseases tend to incorporate more 
and more immunogenic and molecular features of the tu-
mor cells instead of purely architectonic attributes of the 
tissue, as defined in the current WHO classification  [4, 5] , 
the spectrum of final diagnoses in hematopathology with-
in the reach of cytopathology widens. This review pre-
dominantly focuses on studies published in the last 10–15 
years on the application of FC in body cavity effusions, in 
order to discuss the entities as they are defined in the cur-
rent nomenclature of hematologic neoplasia  [4, 5] .
 Technical and Methodological Aspects 
 Flow cytometric analysis of hematolymphoid pro-
cesses in body fluids is a rapid, reproducible, sensitive, 
and quantitative method for immunophenotyping of 
cells, which utilizes a panel of fluorescent dye-tagged an-
tibodies directed mostly against the cell surface markers. 
Demonstration of the presence or absence of light chain 
restriction is essential for the evaluation of B cells with 
the option of characterizing further lymphoma type-spe-
cific markers in cases with light chain restriction. A 
pathologic immunophenotype of T cells with a loss of 
antigen expression or an unusual coexpression of mark-
ers (e.g. CD7, CD4, and CD8) is indicative of T-cell neo-
plasia. Serous effusions are very well suited for studies 
using FC as they naturally consist of suspensions with 
viable cells with well-preserved surface antigens. Cells of 
many types of lymphomas and leukemias are particu-
larly conveniently studied via FC analysis due to their 
abundance in samples and the size and type of the ex-
pressed antigens. Since the body effusions are almost al-
ways submitted for cytopathologic analysis in sufficient 
volumes of over 100 ml (and, if not, this has to be changed/
adapted in the affected institutions), the subject of a low 
cell content is – in contrast to fluids with inherently low 
volumes and cell contents, such as central nervous sys-
tem fluid – not a general problem. Counts of at least sev-
eral thousands of cells can be reached easily for any com-
bination of antibodies.
 There is a wide range of fluorochrome-conjugated an-
tibodies available for FC detected at a different wave-
lengths. The simultaneous detection of multicolored sig-
nals in modern instruments (up to several channels) pro-
vides the opportunity to evaluate multiple antigens at the 
same time, offering means to extensively characterize 
various cell populations. Selection of the antibody panel 
for individual study depends on the individual case; the 
routine panel consists in most cases of at least: CD45, 
κ light chains, λ light chains, CD19, CD20, CD3, CD5, 
CD10, and CD23. The panel can be extended in any spe-
cific case and it can incorporate further markers accord-
ing to the patient history and/or the entity studied (fur-
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ther T-cell markers, monocytic markers, etc.). For opti-
mal results, several thousand signals should be evaluated 
for every antibody combination, requiring in general at 
least a million viable cells in the sample; this prerequisite 
is easily reached in routine samples of body effusions in 
contrast to other specimens of lower cellularity such as 
central nervous system fluid or some FNA. Nonneoplas-
tic reactive effusions usually contain numerous lympho-
cytes and histiocytes; the lymphocytic population con-
sists of at least 90% CD3-positive T cells, with only a few 
CD19+, CD20+ polytypic B cells ( fig. 1 ).
 Indication for FC of Effusions 
 Correct cytologic discrimination between reactive and 
malignant effusions is essential for the clinical manage-
ment of patients with a hematologic disease. The prog-
nostic relevance of malignant effusions has been dis-
cussed controversially in the literature. However, recent 
studies suggest that its presence may be very important; 
in fact, patients with a positive effusion cytology, espe-
cially if present at presentation, have the worst prognosis 
 [2] . Lymphocyte-rich body fluids are common in routine 
cytopathology, and the indication for auxiliary studies 
should be carefully made to avoid cost-ineffective studies 
of reactive lymphocytosis  [6] . In order to ensure the judi-
cious management of resources, it is important that not 
all effusion samples be automatically submitted for FC  [7] 
but that the specimens undergo an initial microscopical 
review by a cytopathologist. This primary review allows 
the exclusion of samples containing obvious inflamma-
tion or nonhematologic malignancy from the lymphatic 
FC work-up. After consideration of the differential diag-
nosis, the proper indication should lead to selection of the 
antibody panel for the FC study. Since the frequency of 
malignant effusions is significantly higher in patients 
with known lymphomas than in those without a hemato-
logic malignancy, the history of any such neoplasia, par-
ticularly of an indolent lymphoma, is the most important 
indication for performance of an FC analysis  [6, 8, 9] . 
However, if the etiology of the microscopically nonneo-
plastic effusion remains unexplained, and especially if it 
is recurrent or accompanied by a striking lymphadenop-
athy, FC should be performed to rule out or prove the 
presence of an indolent lymphoma. The microscopically 
atypical lymphocytes should be examined by FC in order 
to differentiate reactive from neoplastic changes. If the 
fluid tap was performed in the context of an emergency 
clinical presentation for symptomatic relief (in adults or 
in children) and the sample contains an obviously malig-
nant hematologic neoplasia, FC is indispensable since it 
may be rapidly indicative of lymphoma and it may lead to 
prompt employment of the proper treatment as shown by 
Bhaker et al.  [10] for pediatric patients with a precursor 
T-lymphoblastic lymphoma.
a b
 Fig. 1. Pleural fluid of an 88-year-old male patient with a history 
of lung tuberculosis.  a Numerous small lymphocytes in the sedi-
ment of the fluid, practically without mesothelial cells. Papanico-
laou. Original magnification ×400.  b FC demonstrating a reactive 
pattern with numerous CD3-positive T cells (83%) and a small 
CD19-positive B-cell population (9%) without light chain restric-
tion (κ/λ ratio of 1: 1), corresponding to a reactive lymphatic pop-
ulation in the effusion specimen. Lymphocyte-rich pleural effu-
sions with a low mesothelial cell count are often seen in tubercu-
lous pleurisy. 
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 Impact of FC on Cytologic Diagnoses 
 The influence of the results of the FC on the final in-
terpretation of the cytologic evaluation of the effusion 
specimen has been studied recently in several studies.
 In the study of Czader and Ali  [8] , FC was performed 
primarily on effusions of patients with a known history of 
malignant lymphoma, and 115 cases (pleural fluid, n = 86; 
peritoneal fluid, n = 20, and pericardial fluid, n = 9) were 
retrospectively analyzed, with a comparison of the provi-
sional cytopathologic diagnosis and the final diagnosis, 
incorporating the modification by the FC result. Among 
the cytologically malignant cases (n = 43; 37%), there 
were 32 lymphomas, 1 case of acute lymphoblastic leuke-
mia, 1 case of acute myelogenous leukemia, 2 cases of 
 T-cell lymphoma/leukemia, 1 multiple myeloma, 1 Hodg-
kin lymphoma (HL), 4 cases of adenocarcinoma, and 1 
sarcoma. In 18 cases (16%), the provisional cytologic di-
agnosis was later modified by the FC results from atypi-
cal/suspicious to benign (8 cases) and from benign or 
atypical/suspicious to malignant [10 cases: 1 case of 
chronic lymphocytic leukemia (CLL), 2 cases of mantle 
cell lymphoma (MCL), 3 follicular lymphomas (FL), 1 
large-cell lymphoma, 1 plasma cell myeloma, 1 T-cell 
lymphoma, and 1 NK cell leukemia], underscoring the 
importance of FC as an adjunct to cytomorphology in 
body cavity effusions. Cesana et al.  [11] analyzed the com-
parison of FC and cytomorphology results in 92 body 
cavity fluids (61 effusions and 31 bronchoalveolar lavage 
fluids). The overall concordance of both methods was 
75% [56 cases (61%) were double true negative, 11 cases 
(12%) were double true positive, and 2 cases (2%) were 
double false negative]. Among the discordant cases, the 
FC was false negative in 1 case of a cytologically apparent 
PEL in the pleural fluid, while the FC was positive in 8 
falsely negative body fluids (5 pleural and 3 ascites) in cy-
tomorphology only. In cytomorphologically atypical cas-
es, a definite result was achieved by FC in 7 cases of body 
fluids (pleural fluid, n = 6; ascites, n = 1). The κ value in 
relation to the clinical outcome was, in the group of body 
fluids, 0.65 for cytomorphology only and 0.97 for FC, and 
it reached 1.0 for the diagnostic yield of the combined 
method, stressing the advantages of an integrative ap-
proach. Iqbal et al.  [6] retrospectively analyzed 89 body 
fluid specimens (pleural, n = 70; peritoneal, n = 14, and 
pericardial, n = 5). In patients with no history of hemato-
logic disease, the working cytopathologic diagnosis was 
modified from benign/atypical to malignant in only 2 
(11%) cases and from atypical/suspicious to benign in 11 
(33%) cases. In patients with a prior clinical history (38 
cases), FC was positive in 22 cases (58%) and negative in 
16 cases (42%). In 31 cases (35%), the working cytopatho-
logic diagnosis was subsequently modified by the FC re-
sults from atypical/suspicious to benign (13 cases) and 
from benign/atypical to malignant (18 cases). The appli-
cation of FC allowed confidently for either confirmation 
of the diagnosis of malignancy or sure exclusion, lower-
ing the rate of atypical or indeterminate diagnoses. The 
authors concluded that FC should probably be limited to 
cases with: (1) a documented history of hematopoietic 
malignancy, (2) a strong clinical suspicion of malignancy, 
and (3) atypical cytologic or morphologic features suspi-
cious for a hematopoietic malignancy. In the study of Yu 
et al.  [12] , a 4-year retrospective analysis demonstrated 
the application of FC in altogether 2.7% of 6,925 body 
fluids (3.4% of 3,220 body cavity effusions and 1.9% of 
3,705 cerebrospinal fluid specimens). In the category of 
body cavity effusions, FC was applied most often in pleu-
ral effusions (4.5%) and less often in pericardial (1.9%) or 
peritoneal fluids (1.1%). Among the effusion cases with 
FC studies, there were positive or atypical results in 30–
67% of cases, depending on the fluid origin. The cases 
with atypical FC findings or atypical morphologic find-
ings with normal FC were studied further with auxiliary 
methods (immunocytochemistry and molecular genet-
ics), which led to a final definitive diagnosis in a substan-
tial number of cases. Seven of 39 positive cases on FC 
pleural effusion had an as yet not diagnosed lymphoma 
[T-cell lymphomas, n = 2; PEL, n = 1; MCL, n = 1; mar-
ginal-zone lymphoma (MZL), n = 1; diffuse large B-cell 
lymphoma (DLBCL), n = 1, and plasma cell neoplasm, 
n = 1]. Among the negative cases, 6 showed atypical mor-
phologic features and were studied further, similarly to 
the cases with atypical, but nondiagnostic, findings on 
FC, yielding a final definitive diagnosis in an additional 
29 and 17% of cases, respectively. The study of Tong et al. 
 [9] describes an algorithmic approach, including the ap-
plication of FC and other auxiliary studies [immunohis-
tochemistry, polymerase chain reaction for B- and T-cell 
clonality, human herpes virus type 8 (HHV8) status, and 
EBER], to the diagnosis of lymphoproliferative disease in 
effusion samples based on 10 years of experience. A diag-
nosis of a lymphoproliferative disease was made in 133 
pleural effusions, 30 ascites, and 5 pericardial effusions. 
In 77% (122 of 168) of cases a lymphoma diagnosis could 
be definitely made on cytology, and in 23% of cases a sus-
picion of lymphoma was rendered. In 38.2% of cases, the 
diagnosis of lymphoproliferative disease was new, while 
in the remaining cases the manifestation of a known dis-
ease was confirmed. The application of FC was successful 
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in 74.4% of the studied cases (64 of 86), leading in most 
cases to a final diagnosis and covering the whole spec-
trum of lymphoma types: generic diagnoses in 82 patients 
[large-cell lymphomas, NHL not otherwise specified, 
small B-cell NHL (n = 14), and T-cell lymphomas, large 
cell type (n = 2)] or specific subtype diagnoses in 47 pa-
tients [CLL/small lymphocytic lymphoma (SLL), FL, 
MCL, Burkitt lymphoma (BL), PEL (n = 4), T-ALL (n = 
4), posttransplant lymphoproliferative disease (n = 3), pe-
ripheral T-cell lymphoma (n = 2), NOS, and 1 myeloma 
(n = 1)]. Multiple ancillary tests were performed with a 
high success rate as part of the multiparametric approach 
to lymphoma subtyping, similarly to other studies  [13, 
14] .
 Lymphoma/leukemia was reported to be the most fre-
quent cause of malignant effusions in children  [3, 10, 15] . 
In a study of children younger than 18 years with 226 
cases of pleural, peritoneal, and pericardial effusions, 88 
(39%) patients were positive or suspicious of malignancy, 
and among these lymphoma/leukemia was found to be 
the most frequent cause (52%) of malignant effusions. 
The role of FC immunophenotyping as a rapid diagnostic 
 Fig. 2. Pleural effusion of an 83-year-old female patient with a his-
tory of NHL.  a , b Monomorphic middle-sized lymphocytes and a 
few blasts in the sediment smear (Papanicolaou, original magnifi-
cation ×400) ( a ) with immunocytochemical expression of the bcl2 
antigen ( b ).  c FC demonstrating a large CD19-positive B-cell pop-
ulation with κ chain restriction and coexpression of CD10, corre-
sponding to the diagnosis of FL. 
a
b c
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tool for pediatric malignancy in serous cavity effusions 
was studied by Shen et al.  [16] . Among 41 of 103 (40%) 
patients with malignancies, 36 were diagnosed by FC 
(lymphoma, n = 25; acute myeloid leukemia, n = 2; neu-
roblastoma, n = 8, and retinoblastoma, n = 1), and FC 
proved to be especially useful in the category of NHL. 
 B-Cell NHL 
 Chronic Lymphocytic Leukemia/Small Lymphocytic 
Lymphoma 
 CLL/SLL is a common form of an indolent hemato-
logic malignancy that affects the older population and in-
volves predominantly either bone marrow with blood 
lymphocytosis (CLL) or lymph nodes (SLL). For CLL/
SLL in autopsy series, pleural involvement has ranged 
from 3 to 16%  [17] . The appearance of malignant cells of 
this lymphoma type in body cavity effusions is common, 
and it is diagnosed mostly several years after the first di-
agnosis of the tumor  [18, 19] . It can easily be proven via 
FC by demonstration of a light chain-restricted CD19+, 
CD20+ B-cell population coexpressing CD5 and CD23 
but lacking CD10. Since the frequency of CLL/SLL is 
higher in the older population, the coexistence of other 
diseases with the indolent lymphoma will become more 
and more frequent in the future as life expectancy in-
creases. Detection of a small fraction of CLL cells in effu-
sions in patients with stable disease should not divert 
from the search for other, clinically potentially more rel-
evant causes of body cavity fluid accumulation, such as 
congestive heart failure of renal insufficiency. Occasion-
ally, a second malignancy may be observed in the back-
ground of CLL  [20, 21] , and this phenomenon may be 
even more common in the future as cancer turns from a 
uniformly fatal disease into a chronic disease under the 
modern management regimens. It has been shown that 
CLL patients are at risk for the development of further 
nonlymphoid malignancies, such as melanomas, carcino-
mas, or sarcomas, with an estimated 2.5% of CLL patients 
at risk for the development of lung carcinoma. With cy-
tologic methods, including FC, both tumors, i.e. CLL and 
carcinomas, may be confidently diagnosed at the same 
time, as described by Vrettos et al.  [21] . Large-cell lym-
phoma via Richter’s transformation may also occur in 
5–10% of CLL cases.
 Follicular Lymphoma 
 FL ( fig. 2 ) is one of the most common lymphoma types, 
and it accounts for approximately 35% of all NHL cases. 
It is characterized by the t(14; 18) (q32;q21) translocation, 
causing overexpression of the  bcl2 gene. Depending on 
the differentiation, it is either an indolent or an aggressive 
disease and may involve body cavities. FL is usually diag-
nosed histologically via demonstration of the typical nod-
ular growth pattern architecture and immunophenotype. 
Malignant effusions as a first or only presentation of FL 
are an exception  [22], but they belong to the differential 
diagnosis of an unexplained lymphocytic effusion. Dem-
onstration of a CD19+, CD20+ cell population with a 
light chain restriction and CD10 positivity, complement-
ed by demonstration of bcl2 and bcl6 expression as well 
as rearrangement of the  bcl2 gene by fluorescence in situ 
hybridization (FISH), may reliably allow the diagnosis of 
FL in body fluids.
 Mantle Cell Lymphoma 
 MCL ( fig. 3 ) is a mature B-cell lymphoma character-
ized by the translocation t(11; 14)(q13;q32) involving the 
 bcl1 gene. It has a distinct long-term poor prognosis. The 
main involved organs are lymph nodes and the spleen, 
with rare extranodal presentations. It may occasionally be 
demonstrated in effusions, which may also occur as the 
first manifestation of the disease  [14, 23, 24] . The typical 
immunophenotype of MCL including light chain restric-
tion, i.e. CD19+, CD20+, CD5+, CD10–, CD23–, CD3–, 
can elegantly be demonstrated via FC and supplemented 
by a FISH demonstration of the typical gene rearrange-
ment  [14, 24] .
 Marginal-Zone Lymphoma 
 MZL is a rare type of indolent B-cell NHL. MZL is 
only rarely found in effusion fluids. A unique case of 
MZL accompanied by an extensive emperipolesis was re-
cently described by Meykler et al.  [25] . The pleural effu-
sion was notably the first tumor manifestation, and tu-
mor cells were identified by the combined results of FC 
(κ light chain restriction, CD19+, CD20+, CD5–, CD10–, 
and partially CD23+) and immunocytochemistry on the 
cell block (CD20+, CD3–, bcl1–, bcl2–, bcl6–, and TdT–) 
with subsequent confirmation by a bone marrow biopsy. 
 Burkitt Lymphoma 
 BL, an aggressive, translocation-associated lymphoma 
[most commonly of the t(8; 14) type, involving the  c-myc 
gene], with its middle-sized, rather monomorphic cells, is 
quite suitable for immunophenotyping with FC. Effu-
sions are common in BL patients and occur in up to 60% 
of pleural fluids and 90% of asctitic fluids in sporadic BL 
 [26] . FC, with its short turnover time, offers a preferable 
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method for the rapid diagnosis of lymphoma types that 
may present with dramatic symptoms, such as BL or ALL 
 [10, 26] . The typical cytomorphology combined with an 
immunophenotype disclosing a light chain restriction, 
and CD19+, CD20+, CD10+, in the context of a nearly 
100% proliferation index as measured by the Ki67 stain is 
strongly suggestive of a BL diagnosis and should be con-
firmed by the presence of rearrangement of the  c-myc 
gene by further testing (FISH).
 Large-Cell Lymphomas 
 DLBCL is the most common type of aggressive lym-
phoma, accounting for approximately 40% of all lympho-
ma cases. Serous effusions are a common manifestation of 
DLBCL. In the study of Chen et al.  [2] , 18.7% [41/223, 
mostly pleural (n = 34) or pericardial (n = 5) or ascites 
(n = 7), with 5 patients having effusion of 2 body cavities] 
of patients with this lymphoma type had a cytologically 
examined serous effusion during the course of their dis-
ease, with effusions presented already at the time of the first 
a
c b
 Fig. 3. Ascitic fluid of a 52-year-old male patient with retroperito-
neal lymphadenopathy and no history of a tumor.  a Sediment 
smear showing  few normal mesothelial cells and numerous small 
lymphocytes (Papanicolaou, original magnification ×400) with a 
low proliferative activity (MIB1 <5%; not shown).  b FC demon-
strating a large CD19-positive B-cell population with λ chain re-
striction and coexpression of CD5.  c FISH analysis with the fusion 
probe IgH-CCND1 showing fused signals in lymphoma cells (ar-
rows) on sediment smears, indicating the presence of the t(11; 14) 
translocation, diagnostic for Mantle cell lymphoma. Nuclear ex-
pression of cyclin D1 was demonstrated immunocytochemically 
on a cell block (not shown). 
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diagnosis in 58.5% of these patients and the rest occurring 
at 30 days or later. Almost half of these effusions (46%) 
were cytologically diagnosed as malignant, containing 
lymphoma cells. The presence of a malignant effusion in 
this context was a poor prognostic factor and correlated 
with and was worst for patients having the effusion at pre-
sentation. The diagnosis of malignant cells of DLBCL in 
the effusion was made via morphologic analysis and it was 
supplemented in 8 cases by FC, in 2 cases by a clonality 
analysis, and in 6 cases by cytogenetics. One case of an an-
aplastic large-cell lymphoma in pleural fluid was studied 
by FC together with a further 28 histology samples by Kes-
ler et al.  [27] .
 The application of FC to large-cell lymphomas gener-
ally carries a substantial risk of false-negative results due 
to the potential destruction of the fragile cytoplasm of the 
neoplastic cells with a subsequent artificial loss of surface 
antigens during cell sorting, with an FC failure rate of 28% 
mostly for large-cell lymphoma  [9, 12, 27] . Since blastic 
large-cell lymphomas tend to develop a sometimes exten-
sive necrotic change, FC may not be applicable to such 
samples ( fig. 4 a, b). Correlation with conventional micro-
a b
c d
Fig. 4. Examples of lymphatic neoplasia in body fluids, usually not 
requiring FC, for routine diagnostic purposes. The malignant na-
ture of the cells in such cases is obvious on microscopy, and FC 
may not be diagnostic due to fragility of the cytoplasm and ne-
crotic debris.  a A 67-year-old woman – pleural effusion with cells 
of a diffuse large B-cell lymphoma.  b A 66-year-old woman with 
partially necrotic and highly pleomorphic cells of an anaplastic T-
cell lymphoma.  c A 67-year-old man with isolated mesothelial cells 
and an otherwise pure population of malignant plasma cells, cor-
responding to the manifestation of a plasma cell myeloma.  d A 37-
year-old woman with acute myeloid leukemia.  a–d Papanicolaou 
stain. Original magnification ×400. Scale bars =  20 μm. 
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scopic findings is crucial in such cases. Since malignancy 
is almost always obvious in these samples on microscopy, 
the necessary confirmation of the hematologic line of dif-
ferentiation and the exclusion of carcinomas, melanomas, 
and sarcomas may be performed immunocytochemically 
on cell block samples, with FC being less relevant.
 T-Cell NHL 
 T-cell lymphomas appear to be associated with serous 
effusions more frequently than B-cell neoplasms 
do  [3] . Precursor T-lymphoblastic lymphoma (T-LBL) 
comprises approximately 85–90% of lymphoblastic lym-
phoma cases, and it is a neoplasm of lymphoblasts com-
mitted to the T-cell lineage. This subtype frequently man-
ifests as leukemia and therefore the terminology LBL/
acute lymphoblastic leukemia is usually applied. Das et al. 
 [28] reported pleural effusions in 41.6% of  T-cell lympho-
blastic lymphomas as opposed to 3.8% of cases in other 
NHL types. A retrospective review  [29] also indicated that 
there is a significantly higher association with pleural ef-
fusions in patients with lymphoblastic lymphoma (10/14) 
than in those with HL (7 of 60). Bhaker et al.  [10] studied 
the spectrum of cytomorphology and FC immunopheno-
typing in 15 cases of T-LBL, including 10 FNA and 5 ef-
fusion (4 pleural and 1 pericardial) samples. FC demon-
strated positivity for CD2 (15 of 15 cases), surface CD3 
(14 of 15 cases), cytoplasmic CD3 (15 of 15 cases), termi-
nal deoxynucleotidyl transferase (TdT; 8 of 15 cases), 
CD5 (13 of 15 cases), CD10 (7 of 15 cases), and human 
leukocyte antigen-D related (HLA-DR; 1 of 15 cases). 
Dual CD4/CD8 positivity was observed in all cases form-
ing a tight cluster, which is consistent with the cortical 
T-LBL subtype. In 7 cases TdT (nuclear marker) was neg-
ative by FC, while cell block immunocytochemistry was 
positive in all cases. The combination of cytomorphology 
and FC enables an accurate and rapid diagnosis of T-LBL 
on FNA and effusion cytology specimens, thereby obviat-
ing the need for a biopsy. FC is extremely useful in these 
situations because reactive T cells in effusions demon-
strate either CD4 or CD8 positivity but not dual positiv-
ity as was observed in the current study. Infiltration by 
other NHL B-cell types such as CLL/SLL, BL, and MCL 
also may be considered in the differential diagnosis. The 
cytomorphology and clinical spectrum are different in 
these lymphomas; furthermore, FC demonstrates a 
monoclonal B-cell population.
 Peripheral T-cell lymphoma not otherwise specified is 
a rare, aggressive lymphoma type (25–30% of all periph-
eral T cell lymphomas), presenting mostly as a general-
ized lymphadenopathy and rarely affecting extranodal 
sites (skin and gastrointestinal tract). Its presence in body 
cavity fluids is rare. A case of peripheral T-cell lymphoma 
not otherwise specified as a first manifestation in the as-
citic fluid of a patient with an HCV infection was de-
scribed by Ameri et al.  [30] . FC of the fluid sample showed 
an abnormal T-cell population with CD4, CD2, CD5, 
weak CD3, and an absence of CD7 and TdT expression. 
Polymerase chain reaction analysis demonstrated clonal 
T-cell receptor γ gene rearrangement, confirming and es-
tablishing the diagnosis.
 Primary Effusion Lymphoma 
 PEL is a uncommon hematologic malignancy present-
ing in fluids of body cavities without forming tumoral 
masses in immunocompromised patients, mostly with an 
HIV infection, and it is caused by superinfection with 
HHV8  [22, 31] . PEL accounts for about 4% of all HIV-
associated NHL. Morphologically, PEL lymphoma cells 
exhibit high-grade cytologic features, including an im-
munoblastic-to-anaplastic appearance, large nuclei with 
prominent nucleoli, and abundant basophilic cytoplasm. 
Although there have been some reported cases of T-cell 
PEL, lymphoma cells of PEL are considered to be gener-
ally of B-cell origin. PEL are phenotypically variable, 
demonstrating a null immunophenotype with evidence 
of HHV8 infection. PEL show expression of CD45 but 
lack B-cell and T-cell markers, with a variable presence of 
activation markers (CD30, CD38, and CD71) and plasma 
cell differentiation (CD138). As aggressive, blastic lym-
phomas, they are difficult to characterize by FC and are 
mostly diagnosed by immunocytochemistry preferably 
on cell blocks  [9] .
 Hodgkin Lymphoma 
 Pleural effusions are common in patients with HL, oc-
curring in 10–30% of cases  [18, 32] ; however, they are less 
common than in other lymphoma types in children  [29] . 
In the study of Hunter et al.  [33], pleural effusions were 
found radiologically in 26 of 110 patients with HL in var-
ious stages of disease, but only 1 patient underwent tho-
racocentesis with a negative cytologic examination of the 
fluid sample. Since FC is not the method of choice for the 
diagnosis of HL, its diagnostic role in this setting is con-
fined to ruling out the differential diagnosis of an NHL.
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 Plasma Cell Neoplasms 
 Body cavity effusions occurring in the setting of plas-
ma cell myelomas are not common ( ∼ 6% of cases), and 
they are nonneoplastic (nonmyelomatous) in most cases 
due to congestive heart disease or kidney insufficiency, 
liver dysfunction (cirrhosis, hypoalbuminemia), or in-
flammation/infection  [18, 34–36] . Rarely (in less than 1% 
of cases) a myelomatous infiltration of serous membranes 
may be the cause of fluid accumulation ( fig. 4 c). FC with 
the application of CD19, CD45, CD38, CD138, and CD56 
antibodies may be very helpful in diagnosing the presence 
of plasma cell myeloma cells in the fluid specimen if they 
are not apparent on microscopy. In contrast to NHL, no 
expression of CD19 or CD20 is found in plasma cell my-
elomas. Since neoplastic plasma cells often lack surface 
light chain expression, alternative methods for the detec-
tion of their cytoplasmatic presence (ICC or modified FC 
protocols) have to be applied in order to avoid false-neg-
ative results. 
 Myeloproliferative Diseases and Myelodysplastic 
Syndromes 
 The presence of a pleural effusion in myelodysplastic 
syndromes (MDS) is rare and, as in other hemopoietic 
diseases, it is usually a consequence of infection  [17, 18, 
37] . Pleural effusion, secondary to leukemic infiltration, 
is a rare initial manifestation in patients with MDS. Se-
rous effusions due to disease infiltration in myeloprolif-
erative neoplasms, such as chronic myelocytic leukemia, 
have been noted in various case reports throughout the 
literature, mostly in advanced stages, shortly before blas-
tic transformation  [18] . The clonal origin of pleural cells 
in chronic myelocytic leukemia may be identified via con-
ventional cytogenetic methods rather than FC, and they 
may demonstrate the presence of a Philadelphia chromo-
some translocation as well as additional chromosomal al-
terations. The diagnosis of MDS and myeloproliferative 
neoplasms (acute/chronic myeloid leukemia, essential 
thrombocythemia, and polycythemia vera, among oth-
ers) does not typically rely heavily on FC data ( fig. 4 d). 
Thus, in patients with a history of or suspicion for these 
disorders, consultation with a hematopathologist regard-
ing the proper use of FC versus other ancillary studies 
(cytogenetics and molecular genetics) is the preferred ap-
proach. Faiz et al.  [37] reported the largest, nonautopsy 
cohort of patients with acute leukemia and MDS with 
pleural effusions – 111 patients, 58 (52%) of whom had a 
malignant pleural effusion. FC was useful in corroborat-
ing the leukemic cause in 20 of the 22 samples submitted 
for this type of analysis.
 Challenges/Pitfalls in the Application of FC to 
Effusions 
 Knowledge of the typical pitfalls of FC in relation to 
the diagnostics of clinical samples of effusion fluids in the 
context of exclusion or confirmation of the diagnosis of 
a lymphoproliferative disease is essential for the proper 
application of this method. It is important to be familiar 
with the fact that the lymphocytic population of reactive 
effusions consists practically exclusively of T cell lym-
phocytes and that the large CD3+ population is not in-
dicative of a T-cell lymphoma. On the other hand, there 
is no specific or definite T-cell FC malignancy marker, 
and thus in the case of T-cell lymphoma suspicion a mo-
lecular T-cell clonality study has to be performed for def-
inite confirmation. In cases of large-cell lymphomas of 
the B-cell lineage, there is a risk of false-negative diagno-
ses on FC due to extensive necrosis or mechanical de-
struction of fragile cytoplasmic borders of the tumor 
cells, so a correlation with the cytomorphology is obliga-
tory for all cases. There are rare unusual FC patterns, 
such as unspecific antibody binding  [9, 13] or loss of sur-
face light chain expression (e.g. in FL), which may re-
quire additional studies. The tap-related contamination 
of body cavity fluids by blood in patients with CLL may 
lead to the appearance of a small neoplastic cell popula-
tion in the FC of effusion samples and an apparent false-
positive result for the fluid.
 Conclusions 
 The application of immunophenotyping by FC to 
body cavity effusions has proven to be extremely useful 
for subtyping of lymphocytic populations, both in the 
context of recurrent known disease and for as yet nondi-
agnosed lymphomas. The additional use of other auxil-
iary methods, such as immunocytochemistry and FISH, 
allowing demonstration of the molecular background of 
the disease, leads in many cases to the final, clinically rel-
evant definitive specification of the precise type of hema-
tologic malignancy present in the effusions as defined in 
the current WHO classification. These diagnostic per-
spectives stress the important role of cytopathologists in 
the integrative diagnostic process.
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